Clinical trial · no report yet · Phase 1
KANDLELIT-001
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT05067283 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- 16 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 11 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Calderasib; Pembrolizumab; carboplatin; pemetrexed; cetuximab; oxaliplatin; leucovorin; 5-fluorouracil
- Arms
- Arm 1 · Experimental
- Arm 2 · Experimental
- Arm 3 · Experimental
- Arm 4 · Experimental
- Arm 5 · Experimental
- Arm 6 · Experimental
- Enrollment
- 830 (estimated)
- Primary outcomes
- Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
- Number of Participants Who Experience an Adverse Event (AE)
- Number of Participants Who Discontinue Study Treatment Due to an AE
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Dec 17, 2021
- Primary completion
- Feb 25, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05067283 · updated Oct 7, 2026
Publications
linked from the registry- Ma X, Sloman DL, Duggal R, Anderson KD, Ballard JE, Bharathan I, Brynczka C, Gathiaka S, Henderson TJ, Lyons TW, Miller R, Munsell EV, Orth P, Otte RD, Palani A, Rankic DA, Robinson MR, Sather AC, Solban N, Song XS, Wen X, Xu Z, Yang Y, Yang R, Day PJ, Stoeck A, Bennett DJ, Han Y. Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor. J Med Chem. 2024 Jul 11;67(13):11024-11052. doi: 10.1021/acs.jmedchem.4c00572. Epub 2024 Jun 26. PubMed 38924388